Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RIVAROXABAN Cause Product dose omission issue? 810 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 810 reports of Product dose omission issue have been filed in association with RIVAROXABAN (Rivaroxaban). This represents 0.6% of all adverse event reports for RIVAROXABAN.

810
Reports of Product dose omission issue with RIVAROXABAN
0.6%
of all RIVAROXABAN reports
19
Deaths
151
Hospitalizations

How Dangerous Is Product dose omission issue From RIVAROXABAN?

Of the 810 reports, 19 (2.3%) resulted in death, 151 (18.6%) required hospitalization, and 8 (1.0%) were considered life-threatening.

Is Product dose omission issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RIVAROXABAN. However, 810 reports have been filed with the FAERS database.

What Other Side Effects Does RIVAROXABAN Cause?

Gastrointestinal haemorrhage (20,041) Haemorrhage (6,571) Epistaxis (5,629) Rectal haemorrhage (4,501) Off label use (4,463) Haematuria (4,387) Upper gastrointestinal haemorrhage (4,247) Cerebrovascular accident (4,111) Anaemia (3,907) Acute kidney injury (3,735)

What Other Drugs Cause Product dose omission issue?

DUPILUMAB (18,189) USTEKINUMAB (9,405) GUSELKUMAB (9,267) LENALIDOMIDE (8,145) MEPOLIZUMAB (5,873) TOFACITINIB (5,646) VOXELOTOR (5,122) BELIMUMAB (4,671) SECUKINUMAB (4,572) APREMILAST (4,460)

Which RIVAROXABAN Alternatives Have Lower Product dose omission issue Risk?

RIVAROXABAN vs RIVASTIGMINE RIVAROXABAN vs RIVOTRIL RIVAROXABAN vs RIZATRIPTAN RIVAROXABAN vs ROACTEMRA RIVAROXABAN vs ROCURONIUM

Related Pages

RIVAROXABAN Full Profile All Product dose omission issue Reports All Drugs Causing Product dose omission issue RIVAROXABAN Demographics